Following trial failure, Favrille cuts staff

San Diego's Favrille is making massive cuts following the trial failure of Specifid announced earlier this week. The company is axing 132 of its 144 employees, including six of its eight executive officers. There was no word on which of the 12 remaining employees would be managing the company. Specifid was treatment for follicular B-cell non-Hodgkin's lymphoma. The drug failed both primary and secondary endpoints in a Phase III trial. The company's stock plunged 90 percent after the announcement on Tuesday and another 30 percent yesterday.

- see the layoff announcement
- read this report for more

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.